Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 13, 2022

SELL
$1.72 - $2.51 $1,204 - $1,756
-700 Reduced 0.9%
76,720 $159,000
Q1 2022

May 12, 2022

SELL
$1.72 - $2.47 $14,534 - $20,871
-8,450 Reduced 9.84%
77,420 $185,000
Q2 2021

Aug 10, 2021

SELL
$2.06 - $2.67 $5,150 - $6,675
-2,500 Reduced 2.83%
85,870 $191,000
Q1 2021

May 07, 2021

BUY
$2.49 - $6.23 $14,068 - $35,199
5,650 Added 6.83%
88,370 $225,000
Q4 2020

Feb 04, 2021

BUY
$3.48 - $6.47 $146,438 - $272,257
42,080 Added 103.54%
82,720 $535,000
Q3 2020

Oct 29, 2020

BUY
$3.16 - $4.36 $80,580 - $111,180
25,500 Added 168.43%
40,640 $164,000
Q2 2020

Jul 27, 2020

BUY
$1.87 - $3.84 $6,545 - $13,440
3,500 Added 30.07%
15,140 $54,000
Q1 2020

May 08, 2020

BUY
$1.58 - $4.06 $18,391 - $47,258
11,640 New
11,640 $22,000

About OTONOMY, INC.


  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.